2025 AAPS 360 Annual Meeting: Highlights in In Vitro Release and Dissolution Testing and Oral Biopharmaceutics Modeling

Authors: Gousous JA, Bapat P, Chendo CID, Fotaki N, Gray VA, Hermans A, Ju RT, Mendyk A, Mirza T, Mudie D, Nir I, O’Farrell C, Patel S, Salehi N, Shah D, Shen K, Sinko B, Sperry DC, Tiwari S, Tsume Y, Turner DB, Wang Y
Publication: Dissolution Tech
Keywords: biopredictive, biorelevant dissolution, dissolution modeling, In vitro release and dissolution testing (IVRDT), oral biopharmaceutics and absorption modeling (OBAM), Physiologically Based Biopharmaceutics Modeling (PBBM)
Software: GastroPlus®

Abstract

This manuscript highlights key sessions from the In Vitro Release and Dissolution Testing (IVRDT) and Oral Biopharmaceutics and Absorption Modeling (OBAM) communities at the 2025 AAPS PharmSci 360 Annual Meeting (November 9–12, San Antonio, TX). Presentations emphasized a shift toward mechanistic and predictive in vitro and in silico tools, including enzymatic dissolution media, physics-based particle dissolution modeling, physiologically based biopharmaceutics modeling (PBBM) applications for food-effect assessment and specification setting, advanced gastrointestinal simulation platforms, AI-driven formulation optimization, and the complementary role of preclinical animal studies. Collectively, these sessions underscored the value of integrating biorelevant experimentation with computational modeling to streamline and de-risk oral drug development.

By Jozef Al Gousous, Pradnya Bapat, Catarina I. D. Chendo, Nikoletta Fotaki, Vivian A. Gray, Andre Hermans, Rob Tzuchi Ju, Aleksander Mendyk, Tahseen Mirza, Deanna Mudie, Ishai Nir, Connor O’Farrell, Sanjaykumar Patel, Niloufar Salehi, Divyen Shah, Jie Shen, Balint Sinko, David C. Sperry, Sandip Tiwari, Yasuhiro Tsume, David B. Turner, and Yanxing Wang